Emtricitabine/Tenofovir and Darunavir Interaction

Understanding the Emtricitabine/Tenofovir and Darunavir Interaction

FDA-approved prescribing information for these two drugs flags their combination as a minor-severity interaction. Emtricitabine/Tenofovir belongs to the NRTI Combination (HIV PrEP) class and Darunavir belongs to the HIV Protease Inhibitor class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: This combination can cause the level of tenofovir in your blood to rise. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.

Context around a specific patient determines real-world impact. Emtricitabine/Tenofovir has 9 total documented interactions on file in this dataset, and Darunavir has 101. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Your doctor should monitor you closely for any side effects while you are taking these medications together. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.

An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Emtricitabine/Tenofovir or Darunavir based on a web page, speak with your prescriber or pharmacist before making any change.